1. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia;Cappellini;Blood,2006
2. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally administered iron chelator, in comparison to deferoxamine in thalassaemia patients with transfusional iron overload;Piga;Haematologica,2006
3. Phase II clinical evaluation on deferasirox, a once daily oral chelating agent, in paediatric patients with β-thalassaemia major;Galanello;Haematologica,2006
4. Renal tubular function in beta-thalassemia;Sumboonnanonda;Pediatr Nephrol,1998
5. Renal function in pediatric patients with β-thalassemia major;Aldulak;Pediatr Nephrol,2000